Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

被引:663
作者
Niederau, C [1 ]
Heintges, T [1 ]
Lange, S [1 ]
Goldmann, G [1 ]
Niederau, CM [1 ]
Mohr, L [1 ]
Haussinger, D [1 ]
机构
[1] RUHR UNIV BOCHUM,DEPT MED INFORMAT BIOMETR & EPIDEMIOL,W-4630 BOCHUM,GERMANY
关键词
D O I
10.1056/NEJM199605303342202
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background, In patients with chronic hepatitis B, treatment with interferon alfa and the consequent loss of hepatitis B e antigen (HBeAg) from the blood leads to a reduction in inflammatory activity, but the clinical benefits of this treatment have not been established, We evaluated whether HBeAg seroconversion induced by interferon alfa improves clinical outcome. Methods. We studied prospectively a cohort of 103 patients treated with interferon alfa for chronic hepatitis B; the mean (+/-SD) follow-up was 50.0+/-19.8 months, Fifty-three untreated patients served as controls. Results. After treatment with interferon alfa, 53 of 103 patients no longer had detectable HBeAg or hepatitis B virus DNA, although only 10 patients became seronegative for hepatitis B surface antigen (HBsAg) (Kaplan-Meier estimates of cumulative clearance rates at five years, 56.0 percent for HBeAg and 11.6 percent for HBsAg), Of the 53 untreated patients, only 7 spontaneously eliminated HBeAg (28.1 percent at five years), and all remained positive for HBsAg (P<0.001 for the comparison with the treated patients, by the proportional-hazards model). During follow-up, 6 of the 103 treated patients died of liver failure, and 2 needed liver transplantation; all 8 were persistently positive for HBeAg, In another eight treated patients, complications of cirrhosis developed; all but one of these patients remained positive for HBeAg, Overall survival and survival without clinical complications were significantly longer in patients who were seronegative for HBeAg after therapy with interferon alfa than in those who remained seropositive (P=0.004 and P=0.018, respectively), In a regression analysis, clearance of HBeAg was the strongest predictor of survival, Of the 53 untreated patients, 13 had severe complications (including 4 deaths and 1 need for liver transplantation); all 13 continued to be HBeAg-positive. Conclusions. In patients with chronic hepatitis B infection, the clearance of HBeAg after treatment with interferon alfa is associated with improved clinical outcomes. (C) 1996, Massachusetts Medical Society.
引用
收藏
页码:1422 / 1427
页数:6
相关论文
共 20 条
[1]  
ALEXANDER GJM, 1987, LANCET, V2, P66
[2]   RANDOMIZED CONTROLLED TRIAL OF LYMPHOBLASTOID INTERFERON ALFA IN EUROPID MEN WITH CHRONIC HEPATITIS-B VIRUS-INFECTION [J].
BROOK, MG ;
CHAN, G ;
YAP, I ;
KARAYIANNIS, P ;
LEVER, AML ;
JACYNA, M ;
MAIN, J ;
THOMAS, HC .
BRITISH MEDICAL JOURNAL, 1989, 299 (6700) :652-656
[3]   RANDOMIZED CONTROLLED TRIAL OF INTERFERON-ALFA-2A (RBE) (ROFERON-A) FOR THE TREATMENT OF CHRONIC HEPATITIS-B VIRUS (HBV) INFECTION - FACTORS THAT INFLUENCE RESPONSE [J].
BROOK, MG ;
MCDONALD, JA ;
KARAYIANNIS, P ;
CARUSO, L ;
FORSTER, G ;
HARRIS, JRW ;
THOMAS, HC .
GUT, 1989, 30 (08) :1116-1122
[4]   LONG-TERM FOLLOW-UP OF HEPATITIS-B CHRONIC CARRIERS WHO RESPONDED TO INTERFERON THERAPY [J].
CARRENO, V ;
CASTILLO, I ;
MOLINA, J ;
PORRES, JC ;
BARTOLOME, J .
JOURNAL OF HEPATOLOGY, 1992, 15 (1-2) :102-106
[5]   CLINICAL, VIROLOGICAL AND HISTOLOGIC OUTCOME FOLLOWING SEROCONVERSION FROM HEBEAG TO ANTI-HBE IN CHRONIC HEPATITIS TYPE-B [J].
FATTOVICH, G ;
RUGGE, M ;
BROLLO, L ;
PONTISSO, P ;
NOVENTA, F ;
GUIDO, M ;
ALBERTI, A ;
REALDI, G .
HEPATOLOGY, 1986, 6 (02) :167-172
[6]   CHRONIC PERSISTENT HEPATITIS TYPE-B CAN BE A PROGRESSIVE DISEASE WHEN ASSOCIATED WITH SUSTAINED VIRUS-REPLICATION [J].
FATTOVICH, G ;
BROLLO, L ;
ALBERTI, A ;
GIUSTINA, G ;
PONTISSO, P ;
REALDI, G ;
RUOL, A .
JOURNAL OF HEPATOLOGY, 1990, 11 (01) :29-33
[7]   RANDOMIZED, CONTROLLED TRIAL OF RECOMBINANT HUMAN ALPHA-INTERFERON IN PATIENTS WITH CHRONIC HEPATITIS-B [J].
HOOFNAGLE, JH ;
PETERS, M ;
MULLEN, KD ;
JONES, DB ;
RUSTGI, V ;
DIBISCEGLIE, A ;
HALLAHAN, C ;
PARK, Y ;
MESCHIEVITZ, C ;
JONES, EA .
GASTROENTEROLOGY, 1988, 95 (05) :1318-1325
[8]   SEROCONVERSION FROM HEPATITIS-B-E ANTIGEN TO ANTIBODY IN CHRONIC TYPE-B HEPATITIS [J].
HOOFNAGLE, JH ;
DUSHEIKO, GM ;
SEEFF, LB ;
JONES, EA ;
WAGGONER, JG ;
BALES, ZB .
ANNALS OF INTERNAL MEDICINE, 1981, 94 (06) :744-748
[9]   LONG-TERM REMISSION OF CHRONIC HEPATITIS-B AFTER ALPHA-INTERFERON THERAPY [J].
KORENMAN, J ;
BAKER, B ;
WAGGONER, J ;
EVERHART, JE ;
DIBISCEGLIE, AM ;
HOOFNAGLE, JH .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (08) :629-634
[10]   LONG-TERM FOLLOW-UP OF CHRONIC HEPATITIS-B PATIENTS TREATED WITH INTERFERON-ALFA [J].
LOK, ASF ;
CHUNG, HT ;
LIU, VWS ;
MA, OCK .
GASTROENTEROLOGY, 1993, 105 (06) :1833-1838